Corton Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Corton Capital’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,516	Closed	-$86.4K	–	246
2025 Q2	$86.4K	Buy	+12,516	New	+$90.9K	0.1%	318

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Corton Capital's CRBP Position: Q3 2025 in Review

Corton Capital sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 12,516 shares — an estimated $86.4K sold.

Corton Capital first reported a position in CRBP in Q2 2025 and held it in 1 quarter. The position peaked at $86.4K in Q2 2025. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

Corton Capital reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 12,516 Corbus Pharmaceuticals shares in Q3 2025, an estimated $86.4K.
Corton Capital first reported a position in Corbus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Corton Capital's Corbus Pharmaceuticals position peaked at $86.4K in Q2 2025.
81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.